23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Supernus Pharmaceuticals, Inc. › 2025-2026

Supernus Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Supernus Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 376Asset managers, any item
  • 2,326Fund votes
  • June 18, 2026Meeting date

Results at a glance

Meeting of June 18, 2026: 5 items on Supernus Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026: 5 passed (calculated).

Dissent

Notable dissent: 1 director (11.6% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13F, 3.0%, as of September 30, 2026)

Explore Supernus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Supernus Pharmaceuticals, Inc.

These tallies are Supernus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Supernus Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 18, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Frederick M. Hudson 45,058,634---- 2,177,0683,073,181 95%Passed (calculated)—
Elect Director: Charles W. Newhall, III 41,743,154---- 5,492,5483,073,181 88%Passed (calculated)—
2. To approve, on a non-binding basis, the compensation paid to our named executive officers 45,552,6331,675,3557,714 --3,073,181 96%Passed (calculated)—
3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026 49,882,228417,3369,319 --0 99.2%Passed (calculated)—
4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc 41,925,6925,302,0887,922 --3,073,181 89%Passed (calculated)—

Source: Supernus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Supernus Pharmaceuticals, Inc. 2025-2026 meeting

376 asset managers disclosed a vote on at least one Supernus Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Charles W. Newhall, III

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 41,743,154WITHHELD: 5,492,548
Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Charles W. Newhall, III

Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Charles W. Newhall, III”): 41,743,154 for, 5,492,548 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 22,371,221 for, 1,753,571 withheld, 45 abstained.

FOR
FOR: 22,371,221ABSTAIN: 45WITHHOLD: 1,753,571
Largest asset managers voting on “to elect two (2) directors to hold office for the ensuing three years and until their successors have been dul” at Supernus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,583,0590 459,800For
BlackRock6,118,0150 00For
Fidelity1,534,1560 00For
Delaware/Macquarie1,453,0960 00For
State Street3,7160 0998,212Withhold
Dimensional655,1650 00For
Charles Schwab637,1840 00For
Loomis Sayles531,2540 00For
Invesco335,9930 00For
AMG FUNDS312,6810 00For
Bridge Builder Trust258,6280 00For
Victory Capital245,1030 00For
TIAA00 0207,993Withhold
Goldman Sachs207,4000 00For
GLENMEDE FUND INC195,2180 00For
Brighthouse168,9960 09,497Mixed
Lincoln Financial136,5210 040,087Mixed
World Funds Trust167,1260 00For
American Century159,4450 00For
Empower159,0790 00For
First Trust155,2930 00For
THIRD AVENUE TRUST152,3490 00For
JPMorgan00 0131,115Withhold
John Hancock119,4250 00For
Royce111,2760 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Elect Director: Frederick M. Hudson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 45,058,634WITHHELD: 2,177,068
Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Frederick M. Hudson

Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Frederick M. Hudson”): 45,058,634 for, 2,177,068 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 106 asset managers below reported 23,715,749 for, 403,638 withheld, 16 abstained.

FOR
FOR: 23,715,749ABSTAIN: 16WITHHOLD: 403,638
Largest asset managers voting on “to elect two (2) directors to hold office for the ensuing three years and until their successors have been dul” at Supernus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,583,0880 169,800For
BlackRock6,118,0150 00For
Fidelity1,534,1560 00For
Delaware/Macquarie1,453,0960 00For
State Street1,001,8500 078For
Dimensional655,1650 00For
Charles Schwab637,1840 00For
Loomis Sayles531,2540 00For
Invesco335,9930 00For
AMG FUNDS312,6810 00For
Bridge Builder Trust258,6280 00For
Victory Capital245,1030 00For
TIAA207,9930 00For
Goldman Sachs207,4000 00For
GLENMEDE FUND INC195,2180 00For
Brighthouse168,9960 09,497Mixed
Lincoln Financial172,9110 03,697For
World Funds Trust167,1260 00For
American Century159,4450 00For
Empower159,0790 00For
First Trust155,2930 00For
THIRD AVENUE TRUST152,3490 00For
JPMorgan00 0131,115Withhold
John Hancock119,4250 00For
Royce111,2760 00For

Showing the 25 largest of 106 asset managers. All 106 are in the interactive database (link above).

To act upon a proposal to amend the Supernus Pharmaceuticals, Inc

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 41,925,692AGAINST: 5,302,088
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: TO CONSIDER AND ACT UPON A PROPOSAL TO AMEND THE SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE UNDER THE PLAN.

Supernus Pharmaceuticals, Inc.’s own tally for this item (“4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc”): 41,925,692 for, 5,302,088 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 22,106,981 for, 1,969,172 against, 3,810 abstained.

FOR
FOR: 22,106,981AGAINST: 1,969,172ABSTAIN: 3,810
Largest asset managers voting on “TO CONSIDER AND ACT UPON A PROPOSAL TO AMEND THE SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN TO ” at Supernus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,575,55717,346 00For
BlackRock6,118,0150 00For
Fidelity1,534,1560 00For
Delaware/Macquarie1,453,0960 00For
State Street2,338999,590 00Against
Dimensional655,1650 00For
Charles Schwab637,1840 00For
Loomis Sayles531,2540 00For
Invesco335,9930 00For
AMG FUNDS0312,681 00Against
Bridge Builder Trust258,6280 00For
Victory Capital245,1030 00For
TIAA207,9930 00For
Goldman Sachs186,12421,276 00Mixed
GLENMEDE FUND INC195,2180 00For
Brighthouse178,4930 00For
Lincoln Financial140,21836,390 00Mixed
World Funds Trust0167,126 00Against
American Century0159,445 00Against
First Trust155,2930 00For
THIRD AVENUE TRUST0152,349 00Against
JPMorgan131,1150 00For
John Hancock119,4250 00For
Empower118,3240 00For
Royce111,2760 00For

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

To approve, on a non-binding basis, the compensation paid to our named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 45,552,633AGAINST: 1,675,355

Prior year: 96.4% for (June 16, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 371 asset managers

Description as filed by funds: To approve, on a non-binding basis, the compensation paid to our named executive officers.

Supernus Pharmaceuticals, Inc.’s own tally for this item (“2. To approve, on a non-binding basis, the compensation paid to our named executive officers”): 45,552,633 for, 1,675,355 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Supernus Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” (2 managers, 52 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 108 asset managers voting on “To approve, on a non-binding basis, the compensation paid to our named executive officers.” at Supernus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,592,89112 00For
BlackRock6,118,0150 00For
Fidelity1,534,1560 00For
Delaware/Macquarie1,453,0960 00For
State Street1,001,9280 00For
Dimensional655,1650 00For
Charles Schwab637,1840 00For
Loomis Sayles531,2540 00For
Invesco335,9930 00For
AMG FUNDS312,6810 00For
Bridge Builder Trust258,6280 00For
Victory Capital245,1030 00For
TIAA207,9930 00For
Goldman Sachs207,4000 00For
GLENMEDE FUND INC195,2180 00For
Brighthouse168,9969,497 00Mixed
Lincoln Financial172,9113,697 00For
World Funds Trust167,1260 00For
American Century0159,445 00Against
First Trust155,2930 00For
THIRD AVENUE TRUST152,3490 00For
JPMorgan0131,115 00Against
John Hancock119,4250 00For
Empower118,3240 00For
Royce111,2760 00For

Fund voting reports, all 108 managers: 23,571,466 for, 507,676 against, 3,810 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 292 asset managers voting on “To approve, on a non-binding basis, the compensation paid to our named executive officers.” at Supernus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock2,395,465878 00For
State Street2,178,5240 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST1,829,2850 00For
ARMISTICE CAPITAL, LLC1,533,4810 00For
GEODE CAPITAL MANAGEMENT, LLC1,489,6310 00For
Loomis Sayles1,248,3540 00For
Stephens Investment Management Group LLC1,168,7840 00For
Renaissance1,108,2660 00For
GW&K Investment Management, LLC21,2760 00For
Citadel861,5250 00For
Charles Schwab708,0580 00For
Northern Trust590,5560 00For
ASHFORD CAPITAL MANAGEMENT INC570,4440 00For
Sofinnova Investments, Inc.568,1240 00For
Vanguard467,6500 00For
PICTET ASSET MANAGEMENT SA454,6250 00For
Victory Capital407,8060 00For
Woodline Partners LP407,0240 00For
RICE HALL JAMES & ASSOCIATES, LLC402,4540 00For
PRINCIPAL GLOBAL INVESTORS341,6010 00For
MELLON INVESTMENTS Corp338,2230 00For
Freestone Grove Partners LP275,9560 00For
MetLife Investment Management, LLC261,6010 00For
Aberdeen0254,546 00Against
SYSTEMATIC FINANCIAL MANAGEMENT LP229,7121,855 00For

Institutional-manager reports, all 292 managers: 25,392,027 for, 841,740 against, 359 not voted, 877,834 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 49,882,228AGAINST: 417,336

Prior year: 99.4% for (June 16, 2025 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Supernus Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026”): 49,882,228 for, 417,336 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 24,120,946 for, 81 against, 3,810 abstained.

FOR
FOR: 24,120,946AGAINST: 81ABSTAIN: 3,810
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR” at Supernus Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard6,592,9003 00For
BlackRock6,118,0150 00For
Fidelity1,534,1560 00For
Delaware/Macquarie1,453,0960 00For
State Street1,001,85078 00For
Dimensional655,1650 00For
Charles Schwab637,1840 00For
Loomis Sayles531,2540 00For
Invesco335,9930 00For
AMG FUNDS312,6810 00For
Bridge Builder Trust258,6280 00For
Victory Capital245,1030 00For
TIAA207,9930 00For
Goldman Sachs207,4000 00For
GLENMEDE FUND INC195,2180 00For
Brighthouse178,4930 00For
Lincoln Financial176,6080 00For
World Funds Trust167,1260 00For
American Century159,4450 00For
Empower159,0790 00For
First Trust155,2930 00For
THIRD AVENUE TRUST152,3490 00For
JPMorgan131,1150 00For
John Hancock119,4250 00For
Royce111,2760 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Largest Supernus Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,039,721 shares outstanding at the time of that meeting.

Fund voting reports: top Supernus Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on a non-binding basis, the compensation paid to our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 11.36%
2BlackRock 10.54%
3Fidelity 2.64%
4Delaware/Macquarie 2.50%
5State Street 1.73%
6Dimensional 1.13%
7Charles Schwab 1.10%
8Loomis Sayles 0.92%
9Invesco 0.58%
10AMG FUNDS 0.54%
Institutional-manager reports: top Supernus Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on a non-binding basis, the compensation paid to our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 4.13%
2State Street 3.75%
3NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST 3.15%
4ARMISTICE CAPITAL, LLC 2.64%
5GEODE CAPITAL MANAGEMENT, LLC 2.57%
6Loomis Sayles 2.15%
7Stephens Investment Management Group LLC 2.01%
8Renaissance 1.91%
9GW&K Investment Management, LLC 1.55%
10Citadel 1.48%

Reported Supernus Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Supernus Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock8,797,254 15.16%Form 13F, quarter ended March 31, 2026
BlackRock, Inc. and its affiliates8,197,023 14.12%Proxy statement (DEF 14A), table as of April 29, 2026
Vanguard Group6,048,496 10.42%Form 13F, quarter ended March 31, 2026
Jack A. Khattar +3,934,409 6.78%Proxy statement (DEF 14A), table as of April 29, 2026
Millennium Management3,315,973 5.71%Form 13F, quarter ended March 31, 2026
Millenium Management LLC and its affiliates3,281,615 5.65%Proxy statement (DEF 14A), table as of April 29, 2026
Vanguard Portfolio Management3,263,309 5.62%Schedule 13G, filed April 29, 2026
Armistice Capital, LLC2,764,000 4.76%Proxy statement (DEF 14A), table as of April 29, 2026
Dimensional Fund Advisors LP2,712,341 4.67%Proxy statement (DEF 14A), table as of April 29, 2026
State Street2,288,127 3.94%Form 13F, quarter ended March 31, 2026

Percentages above are of 58,039,721 shares outstanding, as reported by Supernus Pharmaceuticals, Inc. on its Form 10-Q dated April 28, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Supernus Pharmaceuticals, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 376 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,326 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding basis, the compensation paid to our named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Supernus Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Supernus Pharmaceuticals, Inc.’s 10-Q dated April 28, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Supernus Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Supernus Pharmaceuticals, Inc. 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/supernus-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.